Pfizer Inc. (FRA:PFE)
Germany · Delayed Price · Currency is EUR | Market Cap | 140.78B +6.7% |
| Revenue (ttm) | 55.85B -0.2% |
| Net Income | 3.80B -59.7% |
| EPS | 0.67 -59.9% |
| Shares Out | n/a |
| PE Ratio | 37.05 |
| Forward PE | 9.68 |
| Dividend | 1.48 (6.06%) |
| Ex-Dividend Date | Jul 24, 2026 |
| Volume | 1,569 |
| Open | 24.79 |
| Previous Close | 24.63 |
| Day's Range | 24.39 - 24.89 |
| 52-Week Range | 20.58 - 25.50 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 3, 2026 |
About Pfizer
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It als... [Read more]
Financial Performance
In 2025, Pfizer's revenue was $62.58 billion, a decrease of -1.65% compared to the previous year's $63.63 billion. Earnings were $7.77 billion, a decrease of -3.24%.
Financial numbers in USD Financial StatementsNews
Pfizer says LITFULO significantly improved repigmentation in patients
Pfizer (PFE) presented results from two Phase 3 trials evaluating the efficacy and safety of LITFULO as a once-daily oral treatment across a wide range of disease extent. In the…
Pfizer's LITFULO Significantly Improved Facial and Total Body Repigmentation in Patients with Nonsegmental Vitiligo
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today presented results from two Phase 3 trials evaluating the efficacy and safety of LITFULO® (ritlecitinib) as a once-daily oral treatment across a...
Trump Medicare drug pricing model may apply to only four companies after exemptions
A Trump administration rule to cut hospital drug prices for Medicare patients may apply to as few as four drugmakers after exempting companies that signed separate "most favored nation" pricing agre...
Florida Attorney General sues Pfizer and CEO over COVID-19 vaccine claims
Florida Attorney General James Uthmeier on Thursday filed a lawsuit against Pfizer and its CEO, Albert Bourla, accusing the drugmaker of misleading consumers about the safety and effectiveness of it...
Florida sues Pfizer over COVID vaccine marketing
Florida Attorney General James Uthmeier filed a lawsuit against Pfizer (PFE) and its CEO Dr. Albert Bourla. Uthmeier said via X: “Weeks ago we learned Fauci and the biomedical state…
Pfizer says Phase 2 study of tilrekimig met primary endpoint
Pfizer (PFE) presented detailed results from an ongoing Phase 2 study investigating tilrekimig in adults with moderate-to-severe atopic dermatitis. The study met its primary endpoint, demonstrating a ...
Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today presented detailed results from an ongoing Phase 2 study investigating tilrekimig (PF-07275315) in adults with moderate-to-severe atopic dermat...
Nurix Therapeutics announces achievement of $7M milestone with Pfizer
Nurix Therapeutics (NRIX) announced the achievement of a $7M research milestone under its strategic collaboration with Pfizer (PFE) for the discovery and development of degrader antibody conjugates. N...
Pfizer Advances Today's Cancer Care and Tomorrow's Potential Breakthroughs at ESMO
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) will present data from 45 company-sponsored, investigator-sponsored, and collaborative research abstracts at the European Society for Medical Oncolog...
Oric Pharmaceuticals initiated with a Buy at BTIG
BTIG analyst Jeet Mukherjee initiated coverage of Oric Pharmaceuticals (ORIC) with a Buy rating and $26 price target. Oric’s rinzimetostat has a potential best-in-class safety profile over Pfizer’s (P...
Pfizer CEO Bourla plans to attend White House state dinner, Reuters reports
Pfizer (PFE) CEO Albert Bourla is expected to attend President Trump’s September 24 state dinner for Chinese President Xi Jinping, as the leaders seek greater stability in U.S.-China relations amid…
Pfizer CEO Bourla plans to attend White House state dinner for China's Xi, source says
Pfizer CEO Albert Bourla plans to attend U.S. President Donald Trump's state dinner for Chinese President Xi Jinping on Thursday evening, according to a source familiar with the matter on Tuesday.
Pfizer Invites Public to View and Listen to Webcast of November 3 Conference Call with Analysts
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EST on Tuesday, ...
Pfizer Transcript: U.S. All Stars Conference
Resource reallocation and commercial focus have driven strong growth in new products and improved efficiency, while a maturing pipeline and targeted portfolio management support future expansion. AI and digital tools are enhancing productivity, and the company is well-positioned in obesity and oncology markets.
Pharmaceutical Companies Push Trump Administration to Protect China Deals
A surge in U.S.-China transactions is drawing scrutiny in Washington, where some lawmakers are pushing to slow the pace of investment.
Pfizer to share portion of increased revenue to U.S. HHS, Bloomberg says
The U.S. Department of Health and Human Services, HHS, will receive a portion of the increased revenue if Pfizer (PFE) raises its drug prices abroad, Rachel Cohrs Zhang of Bloomberg…
Health Canada authorizes Pfizer, BioNTech’s Omicron XFG-adapted Covid-19 vaccine
Pfizer Canada (PFE) and BioNTech (BNTX) announced that Health Canada has authorized the XFG variant-adapted COMIRNATY for active immunization of individuals aged 6 months and older against COVID-19. T...
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Alexandre de Germay, Chief International Commercial Officer, Exe...
Pfizer Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Key 2025 headwinds have been resolved, shifting focus to pipeline and business development. Major investments in innovation, especially in China, and AI deployment are expected to drive future growth. Upcoming catalysts include a robust obesity portfolio and pivotal oncology readouts.
Pfizer aims at air-traffic controllers for Covid-19 vaccine money, WSJ says
In an attempt to get paid for millions of unwanted Covid-19 vaccines, Pfizer (PFE) is taking aim at air-traffic controllers, Benjamin Katz of The Wall Street Journal reports. The company…
Pfizer Makes an Unusual Enemy in $2 Billion Fight Over Unwanted Covid-19 Vaccines
The drugmaker has targeted air-traffic control fees in a dispute with Poland and Romania.
Pfizer price target raised to $30 from $28 at HSBC
HSBC raised the firm’s price target on Pfizer (PFE) to $30 from $28 and keeps a Hold rating on the shares. The firm adjusted targets in the healthcare group to…
Vaxcyte names Luis Jodar chief medical officer, David McAvoy chief legal officer
Vaxcyte (PCVX) announced the appointments of Luis Jodar as chief medical officer and David McAvoy as chief legal officer. Jodar spent 17 years at Pfizer (PFE), most recently as senior…
Hayes: "950 Billion Reasons" to Buy Bonds, PFE & XRAY Buy Opportunities
"I'll give you 950 billion reasons to buy bonds right now," says Thomas Hayes, who gives a contrarian take on why investors should bolster their portfolios in fixed income. He discusses the "seasonali...